我是否应该在膝关节截骨术中添加矫形生物制剂?系统综述。

IF 2.7 Q1 ORTHOPEDICS Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine Pub Date : 2024-12-01 Epub Date: 2024-06-06 DOI:10.1016/j.jisako.2024.06.001
Amit Meena, Riccardo D'Ambrosi, Luca Farinelli, Manish Attri, Ahmed Mabrouk, Norimasa Nakamura, Matthieu Ollivier, Sachin Tapasvi
{"title":"我是否应该在膝关节截骨术中添加矫形生物制剂?系统综述。","authors":"Amit Meena, Riccardo D'Ambrosi, Luca Farinelli, Manish Attri, Ahmed Mabrouk, Norimasa Nakamura, Matthieu Ollivier, Sachin Tapasvi","doi":"10.1016/j.jisako.2024.06.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Orthobiologics has seen a renaissance over the last decade as an adjunct therapy during osteotomy due to the limited inherent regenerative potential of damaged intraarticular tissues.</p><p><strong>Aim or objective: </strong>This systematic review aims to present the latest evidence regarding using orthobiologics with simultaneous high tibial osteotomy (HTO) for knee osteoarthritis. The results of this study may guide surgeons to improve their clinical results and clear the air regarding confusion over whether or not to add orthobiologics to HTO in clinical practice backed by scientific evidence.</p><p><strong>Evidence review: </strong>According to PRISMA guidelines a systematic search for relevant literature was performed in the PubMed (MEDLINE), Scopus, EMBASE, and Cochrane Library databases of all studies published in English from January 1990 to May 2023. The following search terms were entered into the title, abstract, and keyword fields: \"knee\" or \"osteotomy\" AND \"valgus\" or \"varus\" AND \"regenerative medicine\" or \"PRP\" or \"mesenchymal stem cells\" or \"stem cells\" or \"BMAC\" or \"bone marrow\" or \"growth factors\" or \"umbilical cord blood-derived mesenchymal stem cell\" or \"stromal vascular fraction\". The AMSTAR-2 checklist was used to confirm the quality of the systematic review. Randomised controlled trials (RCTs), prospective and retrospective comparative cohort studies, case-control studies, and case series were included. Studies that reported clinical outcomes in patients treated with knee osteotomy for varus/valgus knee with concomitant adjunction of regenerative treatment [Platelet-rich plasma (PRP), Adipose-derived stem cells (ADSC), Human Umbilical Cord Blood-Derived (HUCBD), Mesenchymal Stem Cells (MSC), bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF)] were included. The outcome measures extracted from the studies were the KOOS score, Lysholm score, Subjective IKDC, WOMAC Score, KSS, Tegner, HSS, radiographic tibiofemoral angle, posterior tibial slope and complications. The current systematic review is registered in the PROSPERO Registry (CRD42023439379).</p><p><strong>Findings: </strong>Osteotomy for unicompartmental arthritis with adjunction of orthobiologics such as PRP, ADSC, HVCBD, MSC, BMAC, and SVF presents a consistent statistically significant clinical improvement compared to preoperative scores regardless of the treatment modality used and there were no notable complications associated with the use of these novel agents.</p><p><strong>Conclusions and relevance: </strong>Orthobiologics and knee osteotomies could improve outcomes in patients with knee osteoarthritis desiring Knee preservation surgeries. However, only a few studies are available on the topic to conclude anything with certainty, the patients included in the studies could not be disintegrated based on the grade of osteoarthritis (OA), type, dosage and frequency of administration of orthobiologic and type of additional surgical procedures used. Therefore, better-structured RCTs are required to implement this finding into routine Orthopaedic practice.</p><p><strong>Level of evidence: </strong>Level 4.</p>","PeriodicalId":36847,"journal":{"name":"Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine","volume":" ","pages":"100282"},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should I add orthobiologics to my knee osteotomy practice? A systematic review.\",\"authors\":\"Amit Meena, Riccardo D'Ambrosi, Luca Farinelli, Manish Attri, Ahmed Mabrouk, Norimasa Nakamura, Matthieu Ollivier, Sachin Tapasvi\",\"doi\":\"10.1016/j.jisako.2024.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Orthobiologics has seen a renaissance over the last decade as an adjunct therapy during osteotomy due to the limited inherent regenerative potential of damaged intraarticular tissues.</p><p><strong>Aim or objective: </strong>This systematic review aims to present the latest evidence regarding using orthobiologics with simultaneous high tibial osteotomy (HTO) for knee osteoarthritis. The results of this study may guide surgeons to improve their clinical results and clear the air regarding confusion over whether or not to add orthobiologics to HTO in clinical practice backed by scientific evidence.</p><p><strong>Evidence review: </strong>According to PRISMA guidelines a systematic search for relevant literature was performed in the PubMed (MEDLINE), Scopus, EMBASE, and Cochrane Library databases of all studies published in English from January 1990 to May 2023. The following search terms were entered into the title, abstract, and keyword fields: \\\"knee\\\" or \\\"osteotomy\\\" AND \\\"valgus\\\" or \\\"varus\\\" AND \\\"regenerative medicine\\\" or \\\"PRP\\\" or \\\"mesenchymal stem cells\\\" or \\\"stem cells\\\" or \\\"BMAC\\\" or \\\"bone marrow\\\" or \\\"growth factors\\\" or \\\"umbilical cord blood-derived mesenchymal stem cell\\\" or \\\"stromal vascular fraction\\\". The AMSTAR-2 checklist was used to confirm the quality of the systematic review. Randomised controlled trials (RCTs), prospective and retrospective comparative cohort studies, case-control studies, and case series were included. Studies that reported clinical outcomes in patients treated with knee osteotomy for varus/valgus knee with concomitant adjunction of regenerative treatment [Platelet-rich plasma (PRP), Adipose-derived stem cells (ADSC), Human Umbilical Cord Blood-Derived (HUCBD), Mesenchymal Stem Cells (MSC), bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF)] were included. The outcome measures extracted from the studies were the KOOS score, Lysholm score, Subjective IKDC, WOMAC Score, KSS, Tegner, HSS, radiographic tibiofemoral angle, posterior tibial slope and complications. The current systematic review is registered in the PROSPERO Registry (CRD42023439379).</p><p><strong>Findings: </strong>Osteotomy for unicompartmental arthritis with adjunction of orthobiologics such as PRP, ADSC, HVCBD, MSC, BMAC, and SVF presents a consistent statistically significant clinical improvement compared to preoperative scores regardless of the treatment modality used and there were no notable complications associated with the use of these novel agents.</p><p><strong>Conclusions and relevance: </strong>Orthobiologics and knee osteotomies could improve outcomes in patients with knee osteoarthritis desiring Knee preservation surgeries. However, only a few studies are available on the topic to conclude anything with certainty, the patients included in the studies could not be disintegrated based on the grade of osteoarthritis (OA), type, dosage and frequency of administration of orthobiologic and type of additional surgical procedures used. Therefore, better-structured RCTs are required to implement this finding into routine Orthopaedic practice.</p><p><strong>Level of evidence: </strong>Level 4.</p>\",\"PeriodicalId\":36847,\"journal\":{\"name\":\"Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine\",\"volume\":\" \",\"pages\":\"100282\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jisako.2024.06.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ORTHOPEDICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jisako.2024.06.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

摘要

重要性:在过去十年中,由于受损关节内组织的固有再生潜力有限,骨生物制剂作为截骨术期间的一种辅助疗法得到了复兴:本系统性综述旨在提供有关使用骨生物制剂同时进行高胫骨截骨术(HTO)治疗膝关节骨性关节炎的最新证据。本研究的结果可指导外科医生提高临床效果,并在科学证据的支持下,澄清临床实践中是否在高胫骨截骨术中添加矫形生物制剂的困惑:根据 PRISMA 指南,我们在 PubMed (MEDLINE)、Scopus、EMBASE 和 Cochrane Library 数据库中对 1990 年 1 月至 2023 年 5 月期间用英文发表的所有研究进行了系统检索。在标题、摘要和关键词字段中输入以下检索词:"膝关节 "或 "截骨术"、"外翻 "或 "曲张"、"再生医学 "或 "PRP "或 "间充质干细胞 "或 "干细胞 "或 "BMAC "或 "骨髓 "或 "生长因子 "或 "脐带血间充质干细胞 "或 "基质血管成分"。AMSTAR-2核对表用于确认系统综述的质量。随机对照试验(RCT)、前瞻性和回顾性队列比较研究、病例对照研究和病例系列研究均被纳入其中。纳入的研究报告了接受膝关节截骨术治疗的膝关节外翻/内翻患者的临床疗效,并同时进行了再生治疗[富血小板血浆(PRP)、脂肪来源干细胞(ADSC)、人类脐带血来源干细胞(HUCBD)、间充质干细胞(MSC)、骨髓抽吸物浓缩物(BMAC)、基质血管组分(SVF)]。从研究中提取的结果指标包括 KOOS 评分、Lysholm 评分、主观 IKDC、WOMAC 评分、KSS、Tegner、HSS、影像学胫骨股骨角、胫骨后斜度和并发症。本系统综述已在 PROSPERO 注册中心注册(CRD42023439379):无论采用哪种治疗方式,与术前评分相比,单间室关节炎截骨术与 PRP、ADSC、HUCBD、间充质干细胞、BMAC 和 SVF 等骨生物制剂的辅助治疗在统计学上都有显著的临床改善,而且使用这些新型制剂没有明显的并发症:骨生物制剂和膝关节截骨术可改善希望进行膝关节保留手术的膝关节骨性关节炎患者的治疗效果。然而,目前仅有少数几项相关研究可以得出肯定的结论,而且无法根据骨关节炎(OA)的等级、矫形生物制剂的类型、剂量和给药频率以及所使用的附加手术类型对研究中的患者进行分类。因此,要将这一发现应用到常规骨科实践中,还需要进行结构更合理的 RCT 研究:证据等级:4 级。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Should I add orthobiologics to my knee osteotomy practice? A systematic review.

Importance: Orthobiologics has seen a renaissance over the last decade as an adjunct therapy during osteotomy due to the limited inherent regenerative potential of damaged intraarticular tissues.

Aim or objective: This systematic review aims to present the latest evidence regarding using orthobiologics with simultaneous high tibial osteotomy (HTO) for knee osteoarthritis. The results of this study may guide surgeons to improve their clinical results and clear the air regarding confusion over whether or not to add orthobiologics to HTO in clinical practice backed by scientific evidence.

Evidence review: According to PRISMA guidelines a systematic search for relevant literature was performed in the PubMed (MEDLINE), Scopus, EMBASE, and Cochrane Library databases of all studies published in English from January 1990 to May 2023. The following search terms were entered into the title, abstract, and keyword fields: "knee" or "osteotomy" AND "valgus" or "varus" AND "regenerative medicine" or "PRP" or "mesenchymal stem cells" or "stem cells" or "BMAC" or "bone marrow" or "growth factors" or "umbilical cord blood-derived mesenchymal stem cell" or "stromal vascular fraction". The AMSTAR-2 checklist was used to confirm the quality of the systematic review. Randomised controlled trials (RCTs), prospective and retrospective comparative cohort studies, case-control studies, and case series were included. Studies that reported clinical outcomes in patients treated with knee osteotomy for varus/valgus knee with concomitant adjunction of regenerative treatment [Platelet-rich plasma (PRP), Adipose-derived stem cells (ADSC), Human Umbilical Cord Blood-Derived (HUCBD), Mesenchymal Stem Cells (MSC), bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF)] were included. The outcome measures extracted from the studies were the KOOS score, Lysholm score, Subjective IKDC, WOMAC Score, KSS, Tegner, HSS, radiographic tibiofemoral angle, posterior tibial slope and complications. The current systematic review is registered in the PROSPERO Registry (CRD42023439379).

Findings: Osteotomy for unicompartmental arthritis with adjunction of orthobiologics such as PRP, ADSC, HVCBD, MSC, BMAC, and SVF presents a consistent statistically significant clinical improvement compared to preoperative scores regardless of the treatment modality used and there were no notable complications associated with the use of these novel agents.

Conclusions and relevance: Orthobiologics and knee osteotomies could improve outcomes in patients with knee osteoarthritis desiring Knee preservation surgeries. However, only a few studies are available on the topic to conclude anything with certainty, the patients included in the studies could not be disintegrated based on the grade of osteoarthritis (OA), type, dosage and frequency of administration of orthobiologic and type of additional surgical procedures used. Therefore, better-structured RCTs are required to implement this finding into routine Orthopaedic practice.

Level of evidence: Level 4.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.90
自引率
6.20%
发文量
61
审稿时长
108 days
期刊最新文献
RESPONSE TO ''LETTER TO EDITOR'. Mobile App-Based Monitoring of Recovery After Knee Osteotomy: Patients Take Approximately Five Months to Return to Preoperative Step Counts Despite Limited App Uptake. Return to Sport after First Metatarsophalangeal Arthrodesis in Elite Athletes. Fixation for Osteochondral Lesions of the Talus Leads to Successful Clinical Outcomes in 9 out of 10 Patients: a Systematic Review. The Coraco-Gleno-Scapular Line and Assessing Glenoid Bone Defects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1